GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NYSE:NVO) » Definitions » Institutional Ownership

NVO (Novo Nordisk AS) Institutional Ownership : 7.71% (As of Apr. 16, 2025)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk AS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Novo Nordisk AS's institutional ownership is 7.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Novo Nordisk AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Novo Nordisk AS's Float Percentage Of Total Shares Outstanding is 71.47%.


Novo Nordisk AS Institutional Ownership Historical Data

The historical data trend for Novo Nordisk AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Institutional Ownership Chart

Novo Nordisk AS Historical Data

The historical data trend for Novo Nordisk AS can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 2.82 2.76 2.78 2.72 2.67 2.67 2.73 2.72 2.73 2.77

Novo Nordisk AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.